Auburn Hills, MI, United States of America

John De Kruif

This inventor holds 3 USPTO granted patents. Top assignee: Merus N.v.. Active years: 2018-2022.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2018-2022

Loading Chart...
3 patents (USPTO):Explore Patents

Title: John De Kruif: Innovator in Binding Molecule Technology

Introduction

John De Kruif is a notable inventor based in Auburn Hills, MI (US). He has made significant contributions to the field of biotechnology, particularly in the generation of binding molecules. With a total of 3 patents to his name, De Kruif's work has the potential to impact human therapy significantly.

Latest Patents

Among his latest patents is a method for the generation of binding molecules. This patent provides methods for efficiently and comprehensively screening antibody repertoires from B cells. The goal is to obtain and produce molecules with binding characteristics and functional activities for use in human therapy. This innovative approach could lead to advancements in therapeutic applications.

Career Highlights

John De Kruif has established himself as a key figure in his field. He works at Merus N.V., a company known for its focus on innovative therapeutic solutions. His expertise and contributions have been instrumental in the development of new technologies in biotechnology.

Collaborations

Throughout his career, De Kruif has collaborated with notable professionals in the industry, including Ton Logtenberg and Mark Throsby. These collaborations have further enhanced his work and contributed to the advancement of binding molecule technology.

Conclusion

In summary, John De Kruif is a prominent inventor whose work in binding molecules is paving the way for future advancements in human therapy. His patents and collaborations reflect his commitment to innovation in biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…